IP Library › Granted Patent US 12,410,440
Granted Patent B2
US 12,410,440 · App. 18/518,212 · Granted Sep 9, 2025

ABCA4 trans-splicing molecules

Inventors: Rebekka Krumbach (Boston, MA); Scott Dooley (Boston, MA); Akiko Doi (Boston, MA); Kirk Burkhart (Boston, MA); Jesse Gray (Boston, MA); Lingtao Peng (Boston, MA); Dennis Wu (Boston, MA); Akiko Noma (Boston, MA); Kirk Gosik (Boston, MA); Shimyn Slomovic (Boston, MA); Adam Clemens (Boston, MA); Robert Bell (Boston, MA)
Assignee: Ascidian Therapeutics, Inc.
C12N15/85A61K48/005C07K14/705C12N9/22C12N15/11C12N15/86C12N15/907C12N2310/20C12N2320/33C12N2750/14143C12N2750/14145C12N2750/14171C12N2830/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,440
App. No.
18/518,212
Granted
Sep 9, 2025
Kind
B2
Abstract

Provided herein are nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs); RNA exon editing molecules) capable of correcting mutations in the ABCA4 gene. Such molecules are useful in the treatment of disorders such as ABCA4-associated retinal dystrophies (e.g., Stargardt Disease or cone-rod dystrophy). Also described herein are methods of using the nucleic acid trans-splicing molecules described herein to correct mutations in ABCA4, thereby treating disorders associated with mutations in ABCA4 and use of the nucleic acid trans-splicing molecules described herein for treating disorders associated with mutations in ABCA4 and in the preparation of medicaments for the treatment of disorders associated with mutations in ABCA4.

Claims (29)

1. A nucleic acid trans-splicing molecule comprising:

(a) a coding domain sequence (CDS) comprising at least one ABCA4 exon having at least one nucleotide variation relative to a wild-type sequence of the ABCA4 exon at a cryptic splice site within the ABCA4 exon, wherein the at least one nucleotide variation comprises a synonymous nucleotide substitution at a branchpoint of the cryptic splice site or splice site of the cryptic splice site, or comprises synonymous nucleotide substitutions at both a branchpoint of the cryptic splice site and a splice site of the cryptic splice site, wherein the amino acid sequence encoded by the ABCA4 exon is not altered by the synonymous nucleotide substitution or substitutions;

(b) a binding domain that is complementary to a binding site within an endogenous ABCA4 pre-mRNA; and

(c) a splicing domain.

2. The nucleic acid trans-splicing molecule of claim 1 , wherein the cryptic splice site is set forth in one of SEQ ID NOs: 133-670.

3. The nucleic acid trans-splicing molecule of claim 1 , wherein the cryptic splice site is set forth in one of SEQ ID NOs: 133, 134, 135, 137, 138, 139, 140, 141, 142, or 147.

4. The nucleic acid trans-splicing molecule of claim 1 , wherein the CDS comprises one or more of SEQ ID NOs: 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 127, 129, 131, 673, 674, 679, 682, 685, 721, 722, 785, 791, 938, 951, 993, 997, 999, 1010, 1040, 1047, 1070, 1117, or 1169.

5. The nucleic acid trans-splicing molecule of claim 1 , wherein the CDS comprises exons 1-22 of ABCA4 having the at least one nucleotide variation.

6. The nucleic acid trans-splicing molecule of claim 5 , wherein the CDS comprises any one of SEQ ID NOs: 56-59.

7. The nucleic acid trans-splicing molecule of claim 6 , wherein the CDS comprises SEQ ID NO: 56.

8. The nucleic acid trans-splicing molecule of claim 1 , wherein the binding domain anneals to a sequence within intron 22 of the endogenous ABCA4 pre-mRNA.

9. The nucleic acid trans-splicing molecule of claim 8 , wherein the binding domain comprises SEQ ID NO: 18 or 20.

10. The nucleic acid trans-splicing molecule of claim 1 , wherein the splicing domain comprises the sequence GTAAGT.

11. The nucleic acid trans-splicing molecule of claim 1 , further comprising a 5′ untranslated region.

12. The nucleic acid trans-splicing molecule of claim 1 , further comprising a 3′ transcription terminator domain comprising SEQ ID NO: 33.

13. The nucleic acid trans-splicing molecule of claim 1 comprising, operatively linked in a 5′-to-3′ direction:

(a) a 5′ untranslated region comprising SEQ ID NO: 13 or SEQ ID NO: 64;

(b) a CDS comprising any one of SEQ ID NOs: 53-59;

(c) a splicing domain comprising the sequence GTAAGT;

(d) two stop codons, wherein the sequence of the first of the two stop codons overlaps in part with the splicing domain sequence and wherein the sequence of the splicing domain in combination with the two stop codons comprises SEQ ID NO: 68;

(e) a binding domain comprising SEQ ID NO: 18 or SEQ ID NO: 20; and

(f) a 3′ transcriptional terminator domain comprising SEQ ID NO: 66.

14. The nucleic acid trans-splicing molecule of claim 1 , further comprising a 3′transcription terminator domain comprising SEQ ID NO:66.

15. The nucleic acid trans-splicing molecule of claim 7 , comprising the sequence of SEQ ID NO: 69.

16. The nucleic acid trans-splicing molecule of claim 7 , comprising the sequence of SEQ ID NO: 78.

17. The nucleic acid trans-splicing molecule of claim 7 , comprising the sequence of SEQ ID NO: 90.

18. The nucleic acid trans-splicing molecule of claim 1 , which comprises the synonymous nucleotide substitution at the branchpoint of the cryptic splice site.

19. The nucleic acid trans-splicing molecule of claim 1 , which comprises the synonymous nucleotide substitution at the splice site of the cryptic splice site.

20. The nucleic acid trans-splicing molecule of claim 1 , which comprises nucleotide substitutions at each of the branchpoint of the cryptic splice site and the splice site of the cryptic splice site.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2024
From: KRUMBACH, REBEKKA; DOI, AKIKO; BURKHART, KIRK; GRAY, JESSE; PENG, LINGTAO; WU, DENNIS; NOMA, AKIKO; SLOMOVIC, SHIMYN; CLEMENS, ADAM; BELL, ROBERT; DOOLEY, SCOTT; GOSIK, KIRK
To: ASCIDIAN THERAPEUTICS, INC.
Reel/Frame 066812/0546 →
Continuity (4)
Continuation 18316959 · May 12, 2023
Provisional Application 63478472 · Jan 4, 2023
Provisional Application 63341665 · May 13, 2022
Related Publication 20240091381A1 · Mar 21, 2024
References Cited (87)
US 6013487A · Mitchell · 2000 [cited by applicant]
US 6280978B1 · Mitchell et al. · 2001 [cited by applicant]
US 7943374B2 · Hildinger · 2011 [cited by applicant]
US 7968334B2 · Puttaraju et al. · 2011 [cited by applicant]
US 8053232B2 · Puttaraju et al. · 2011 [cited by applicant]
US 8076461B2 · Pearce et al. · 2011 [cited by applicant]
US 8173377B2 · Agris et al. · 2012 [cited by applicant]
US 8236557B2 · Dongsheng et al. · 2012 [cited by applicant]
US 8323910B2 · Agris et al. · 2012 [cited by applicant]
US 8697355B2 · Agris et al. · 2014 [cited by applicant]
US 8735366B2 · Bauer et al. · 2014 [cited by applicant]
US 9303078B2 · Garcia et al. · 2016 [cited by applicant]
US 9976143B2 · Krainer et al. · 2018 [cited by applicant]
US 10913947B2 · Aznarez et al. · 2021 [cited by applicant]
US 10987433B2 · Bennett et al. · 2021 [cited by applicant]
US 11096956B2 · Aznarez et al. · 2021 [cited by applicant]
US 11517583B2 · Patzel et al. · 2022 [cited by applicant]
US 20130059901A1 · Bauer et al. · 2013 [cited by applicant]
US 20130071951A1 · Agris et al. · 2013 [cited by applicant]
US 20140087444A1 · Bennett et al. · 2014 [cited by applicant]
US 20140243388A1 · Hastings · 2014 [cited by applicant]
US 20150202269A1 · Beltran et al. · 2015 [cited by applicant]
US 20150252358A1 · Maeder et al. · 2015 [cited by applicant]
US 20170342414A1 · Collin et al. · 2017 [cited by applicant]
US 20210002667A1 · Schnepp · 2021 [cited by examiner]
US 20210155938A1 · Johnson et al. · 2021 [cited by applicant]
US 20220204989A1 · Fisher et al. · 2022 [cited by applicant]
US 20230340469A1 · Nelles · 2023 [cited by applicant]
EP 2151248A1 · 2010 [cited by applicant]
WO WO9722250A1 · 1997 [cited by applicant]
WO WO9814275A1 · 1998 [cited by applicant]
WO WO0149745A1 · 2001 [cited by applicant]
WO WO03003014A1 · 2003 [cited by applicant]
WO WO03069311A2 · 2003 [cited by applicant]
WO WO03072739A2 · 2003 [cited by applicant]
WO WO03104412A2 · 2003 [cited by applicant]
WO WO03104416A2 · 2003 [cited by applicant]
WO WO2004006678A1 · 2004 [cited by applicant]
WO WO2004038380A2 · 2004 [cited by applicant]
WO WO2005023990A2 · 2005 [cited by applicant]
WO WO2005070023A2 · 2005 [cited by applicant]
WO WO2005070948A1 · 2005 [cited by applicant]
WO WO2006026611A2 · 2006 [cited by applicant]
WO WO2009103562A1 · 2009 [cited by applicant]
WO WO2010012472A1 · 2010 [cited by applicant]
WO WO2014062801A1 · 2014 [cited by applicant]
WO WO2014170480A1 · 2014 [cited by applicant]
WO 2016005524A1 · 2016 [cited by applicant]
WO WO2017087900A1 · 2017 [cited by examiner]
WO WO2017106370A1 · 2017 [cited by applicant]
WO WO2019027869A1 · 2019 [cited by applicant]
WO WO2019204514A1 · 2019 [cited by examiner]
WO 2020214990A1 · 2020 [cited by applicant]
WO WO2020214973A1 · 2020 [cited by examiner]
WO 2020223180A1 · 2020 [cited by applicant]
WO WO2021034717A1 · 2021 [cited by applicant]
WO WO2021076656A1 · 2021 [cited by applicant]
WO WO2021172925A1 · 2021 [cited by applicant]
WO WO2022067228A1 · 2022 [cited by applicant]
WO WO2022220968A1 · 2022 [cited by applicant]
WO WO2023034582A1 · 2023 [cited by applicant]
WO WO2023205694A2 · 2023 [cited by applicant]
WO WO2023215761A1 · 2023 [cited by applicant]
WO WO2023220742A2 · 2023 [cited by applicant]
Berkman printout from https://www.genome.gov/genetics-glossary/Substitution/ dated Mar. 18, 2025 pp. 1/4 to 4/4 (Year: 2025). [cited by examiner]
Bacchi, N. et al., “Splicing-Correcting Therapeutic Approaches for Retinal Dystrophies: Where Endogenous Gene Regulation and Specificity Matter,” Investigative Ophthalmology & Visual Science, 2014;55:3285-3294. [cited by applicant]
Bennicelli, J. et al., “CEP290 Minigene Model of Common Splice Site Mutation in Leber Congenital Amaurosis,” Molecular Therapy, 2012:S167. [cited by applicant]
Collin, R. et al., “Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290,” Molecular Therapy Nucleic Acids, 2012;1:1-7. [cited by applicant]
Dooley, S.J. et al., “Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA,” Molecular Therapy-Nucleic Acids, 2018; 12:294-308. [cited by applicant]
Gao, J. et al., “A conserved intronic U1 snRNP-binding sequence promotes trans-splicing in Drosophila,” Genes & Development, 2015;29:760-771. [cited by applicant]
Garanto, A. et al., “In Vitro and In Vivo Rescue of Aberrant Splicing in CEP290-associated LCA by Antisense Oligonucleotide Delivery,” Human Molecular Genetics, 2015;25(12):2552-2563. [cited by applicant]
Garanto, A. et al., “Species-Dependent Splice Recognition of a Cryptic Exon Resulting from a Recurrent Intronic CEP290 Mutation that Causes Congenital Blindness,” International Journal of Molecular Sciences, 2015;16(3):… [cited by applicant]
Gerard, X. et al., “Intravitreal Injection of Splice-switching Oligonucleotides to Manipulate Splicing in Retinal Cells,” Molecular Therapy, 2015;4:1-8. [cited by applicant]
Havens, M. A. et al., “Targeting RNA Splicing for Disease Therapy,” Wiley Interdiscip Rev RNA, 2013;4(3):247-266. [cited by applicant]
Helou, J et al., “Mutation analysis of NPHP6/CEP290 in patients with Joubert syndrome and Senior Loken syndrome,” Journal of Medical Genetics, 2007;44(10):657-663. [cited by applicant]
International Search Report and Written Opinion dated Feb. 16, 2017 issued in International Patent Application No. PCT/US2016/062941. [cited by applicant]
Koller, U.A. et al., “A Novel Screening System Improves Genetic Correction by Internal Exon Replacement,” Nucleic Acids Research, 2011;39(16):e108. [cited by applicant]
Liemberger, B. et al., “RNA Trans-Splicing Modulation via Antisense Molecule Interference,” International Journal of Molecular Sciences, 2018;19(3):762. [cited by applicant]
Lu, X. et al., “The tRNA-like small noncoding RNA mascRNA promotes global protein translation,” EMBO Rep., 2020;21(12):e49684. [cited by applicant]
Maia-Lopes, S. et al., “ABCA4 mutations in Portuguese Stargardt patients: identification of new mutations and their phenotypic analysis,” Molecular Vision, 2009; 15:584-591. [cited by applicant]
Monjaret, F. et al., “Cis-splicing and translation of the pre-trans-splicing molecule combine with efficiency in spliceosome-mediated RNA trans-splicing,” Mol Ther., 2014;22(6):1176-1187. [cited by applicant]
Parker, M.A. et al., “Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5,” Am J Op… [cited by applicant]
Wilusz, J.E. et al., “A triple helix stabilizes the 3′ ends of long noncoding RNAs that lack poly(A) tails,” Genes & Development, 2012;26(21):2392-2407. [cited by applicant]
Zhang, N. et al., “Protein misfolding and the pathogenesis of ABCA4-associated retinal degenerations,” Human Molecular Genetics, 2015;24(11):3320-3237. [cited by applicant]
Coady, et al., Development of a single vector system that enhances trans-splicing of SMN2 transcripts, PLoS ONE, 3(10):e3468, (2008). [cited by applicant]
Koller, et al., Trans-Splicing improvement by the combined application of antisense strategies, International Journal of Molecular Sciences, 16:1179-1191, (2015). [cited by applicant]
International Search Report and Written Opinion issued in PCT/US2023/066969, mailed Nov. 8, 2023. [cited by applicant]